Liver Diseases  >>  Isentress (raltegravir)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Isentress (raltegravir) / Merck (MSD)
NCT00782301: Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Withdrawn
4
0
US, Canada, Europe
maraviroc, Selzentry, etravirine
ViiV Healthcare, Pfizer
Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic
02/10
02/10
NCT01225705 / 2009-015904-24: Safety Study of Raltegravir in HIV/HCV Co-infected Patients

Withdrawn
4
0
Europe
raltegravir, Atazanavir/ritonavir
University Hospital, Bonn, Dr. Axel Baumgarten, Berlin, Dr. Christoph Stephan, Frankfurt/M, Dr. Stefan Esser, Essen, Dr. Keikawus Arastéh, Berlin, Prof. Dr. Hans-Jürgen Stellbrink, Hamburg, Dr. Thomas Lutz, Frankfurt/M, Dr. Jörg Gölz , Berlin
HIV, Hepatitis C
08/12
08/12
NCT01285050: Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

Completed
4
20
US
Antiretroviral therapy (ART), raltegravir, Isentress, Emtricitabine and tenofovir disoproxil fumarate, Truvada
Johns Hopkins University, National Institute on Drug Abuse (NIDA)
HIV Infection, Hepatitis C
04/15
04/15
STERAL, NCT01900015 / 2013-002111-10: Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection

Completed
4
45
Europe
Raltegravir, Issentres, Efavirenz, Sustiva
Juan Macías
HCV Coinfection, HIV Infection
01/17
01/17

Download Options